PLN-1474
Non-alcoholic Steatohepatitis (NASH) / Liver Fibrosis
PreclinicalActive (Novartis Collab)
Key Facts
Indication
Non-alcoholic Steatohepatitis (NASH) / Liver Fibrosis
Phase
Preclinical
Status
Active (Novartis Collab)
Company
About Pliant Therapeutics
Pliant Therapeutics is a clinical-stage biotech focused on discovering and developing breakthrough therapies for fibrotic diseases, a class of serious conditions with high unmet medical need. The company's scientific foundation is built on targeting tissue-specific integrins to inhibit TGF-β activation, aiming for a superior therapeutic profile compared to broad TGF-β inhibitors. Its lead asset, bexotegrast, has demonstrated promising Phase 2a data in IPF and PSC, positioning the company to potentially address multi-billion dollar markets. Pliant's strategy leverages a proprietary integrin platform to build a pipeline of oral therapies for fibrosis across multiple organs.
View full company profile